Association between kidney function and genetic polymorphisms in atherosclerotic and chronic kidney diseases: A cross-sectional study in Japanese male workers

Yoko Kubo, Takahiro Imaizumi, Masahiko Ando, Masahiro Nakatochi, Yoshinari Yasuda, Hiroyuki Honda, Yachiyo Kuwatsuka, Sawako Kato, Kyoko Kikuchi, Takaaki Kondo, Masamitsu Iwata, Toru Nakashima, Hiroshi Yasui, Hideki Takamatsu, Hiroshi Okajima, Yasuko Yoshida, Shoichi Maruyama

1 Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan, 2 Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 3 Department of CKD Initiatives, Nagoya University Graduate School of Medicine, Nagoya, Japan, 4 Department of Biotechnology, Graduate School of Engineering, Nagoya University, Nagoya, Japan, 5 Program in Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan, 6 Safety and Health Promotion Division, Toyota Motor Corporation, Toyota, Japan, 7 R & D Management Division, Toyota Motor Corporation, Toyota, Japan, 8 Innovative Research Center for Preventative Medical Engineering, Nagoya University, Nagoya, Japan

☯ These authors contributed equally to this work.

* mando@med.nagoya-u.ac.jp

Abstract

Background

Several single nucleotide polymorphisms (SNPs) have been implicated in the predisposition to chronic kidney disease (CKD). Atherosclerotic disease is deeply involved in the incidence of CKD; however, whether SNPs related to arteriosclerosis are involved in CKD remains unclear. This study aimed to identify SNPs associated with CKD and to examine whether risk allele accumulation is associated with CKD.

Methods

We conducted a cross-sectional study using data of 4814 male workers to examine the association between estimated glomerular filtration rate (eGFR) and 59 candidate polymorphisms (17 CKD, 42 atherosclerotic diseases). We defined the genetic risk score (GRS) as the total number of risk alleles that showed a significant association in this analysis and examined the relationship with CKD (eGFR < 60 ml/min/1.73m²). Multivariate logistic regression, discrimination by area under the receiver operating characteristic curve, integrated discrimination improvement (IDI), and category-free net reclassification improvement (cNRI) were evaluated.

Results

In total, 432 participants were categorized as having CKD. We found eight candidate SNPs with P value < 0.05 (CX3CR1 rs3732379, SHROOM3 rs17319721, MTP rs1800591, ...)
Kidney function and genetic polymorphisms of atherosclerotic diseases and chronic kidney diseases

(PIP5K1B rs4744712, APOA5 rs662799, BRAP rs3782886, SPATA5L1 rs2467853, and MCP1 rs1024611) in the multivariate linear regression adjusted for age, body mass index, systolic blood pressure, and fasting blood glucose. Among these eight SNPs, BRAP rs3782886 and SPATA5L1 rs2467853 were significantly associated with eGFR (false discovery rate < 0.05). GRS was significantly associated with CKD (odds ratio, 1.17; 95% confidence interval, 1.09–1.26). C-statistics improved from 0.775 to 0.780 but showed no statistical significance. However, adding GRS significantly improved IDI and cNRI (0.0057, P = 0.0028, and 0.212, P < 0.001, respectively).

Conclusions
After adjustment for clinical factors, kidney function was associated with BRAP rs3782886 and SPATA5L1 rs2467853 and the GRS for CKD that we developed was associated with CKD.

Introduction
Chronic kidney disease (CKD) is an independent risk factor for end-stage renal disease (ESRD), cardiovascular disease (CVD), and all-cause mortality in the general population [1–4]. The number of patients with CKD is approximately 13.3 million, representing about 13% of the Japanese adult population [5]. The incidence of CKD stage III or higher increases with age [6]. Moreover, lifestyle-related chronic diseases mainly develop in middle age; thus, predicting the risk of kidney disease in this age group is vital to help prevent the progress towards ESRD and CVD.

Several population-based cohort studies have identified clinical factors associated with CKD, including age, hypertension, diabetes mellitus, and smoking [6,7]. These are also common risk factors for developing atherosclerotic diseases [8–11]. While there are numerous clinical risk factors for CKD, genetic factors also contribute to the development of CKD. Based on genome-wide association studies (GWAS) and candidate gene studies, various single nucleotide polymorphisms (SNPs) have been associated with CKD [12–17]. CKD and atherosclerotic diseases have common risk factors; hence, the genetic background may also be common.

We have reported a number of studies that examined several SNPs associated with chronic lifestyle diseases, such as hypertension, obesity, and metabolic syndrome, among medical checkup examinees [18–20]. We developed an SNPs measuring system to evaluate the risk for chronic lifestyle diseases, which includes SNPs related to CKD and atherosclerotic diseases, such as hypertension, stroke, coronary artery disease, and carotid artery disease. In this study, we used the same SNPs and examined their association with kidney function.

This study aimed to evaluate the role of SNPs related to CKD and atherosclerotic diseases in estimated glomerular filtration rate (eGFR) among Japanese male workers and to determine whether the total number of risk alleles is associated with CKD. The results can be useful to predict CKD risk among middle-aged men with or without atherosclerotic risk factors based on the number of genetic risk alleles.

Materials and methods
Study participants
All male employees of Toyota Motor Co., Ltd. in Japan and those who participated in the annual health examination in 2010 were enrolled in this study. Only those who consented to
DNA sampling were included, and the DNA samples were obtained between 2011 and 2014 from 5112 individuals. In this analysis, we excluded those whose creatinine level data were missing. Consequently, the final number of study participants was 4814. The study protocol was approved by the ethics committee of Nagoya University School of Medicine (No. 1089–4), and the study was conducted in accordance with the guidelines of the Declaration of Helsinki. All the participants provided written informed consent. This trial was registered at umin.ac.jp as UMIN000016266.

Lifestyle evaluation

The lifestyle of participants was evaluated using self-administered questionnaires, which included items on smoking, stress, exercise habits, and drinking habits. Smoking was defined as the current smoking status of the participants and stress as self-reported psychological stress. Responses for drinking habits were divided into four categories: none, <2 days/week, 3–6 days/week, and every day. Exercise habits were also divided into three categories: none, <6 days/week, and every day.

Clinical parameters and outcome definition

The health examinations included physical measurements and serum biochemical measurements. Body mass index (BMI) was calculated as follows: weight (kg)/height (m²), while blood pressure (BP) was measured in the sitting position using an automatic sphygmomanometer (Kentaro HBP-9020; Omron, Tokyo, Japan).

The biochemical measurements included total cholesterol, triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), fasting blood glucose (FBG), HbA1c, uric acid (UA), and creatinine levels. The following equation was employed to calculate eGFR, as described by Matsuo et al. [21]:

\[
\text{Estimated GFR (eGFR)} = 194 \times \text{standardized serum creatinine}^{-0.1094} \times \text{age}^{-0.287}
\]

Moreover, the positive result in the urine dipstick test represents urinary protein. CKD was defined as eGFR < 60 ml/min/m².

SNP selection

In our previous study, we developed an SNP measuring system including 99 candidate SNPs that were associated with coronary heart disease, hypertension, dyslipidemia, diabetes mellitus, hyperuricemia, renal disease, or obesity [18]. Here, we selected 59 candidate SNPs that were associated with CKD and diseases related to atherosclerosis, including hypertension, coronary artery disease, stroke, and carotid artery disease. Detailed information of SNPs is shown in S1 Table.

Genotyping the SNPs

DNA was anonymously extracted from blood samples of the participants (0.2 mL each) at DNA Chip Research Inc. (QIAamp series; QIAGEN K.K., Tokyo, Japan). All SNPs were genotyped using the DigiTag2 assay [22].

Primers, probe sequences, and polymerase chain reaction conditions for the SNPs in the original cohort were similar to those described previously [18]. All the laboratory technicians were blinded to the participants’ identity, demographic characteristics, and study outcomes. Our study’s laboratory protocol was registered at http://dx.doi.org/10.17504/protocols.io/jmick4e
Statistical analysis

The clinical characteristics of the participants are presented as numbers and percentages for qualitative variables (i.e., smoking, exercise habits, and drinking habits), and as means and standard deviations or medians and interquartile ranges (IQRs) for quantitative variables (i.e., age, BMI, abdominal circumference, systolic blood pressure (SBP), and diastolic blood pressure (DBP)) as appropriate.

For each SNP, a score of 0, 1, or 2 was assigned depending on the number of minor alleles. For example, if A is the minor allele, the genotype aa corresponds to zero minor alleles, Aa corresponds to the presence of one minor allele, and AA corresponds to the presence of two minor alleles. The SNP score was treated as a continuous variable.

Initially, we examined the association between eGFR and SNPs using linear regression, assuming an additive genetic model adjusted for age, BMI, SBP, and FBG. Considering the multiple comparisons of genotypes with eGFR, the false discovery rate (FDR) was calculated from the distribution of P values for regression analysis of the 59 polymorphisms. We considered polymorphisms with an FDR of < 0.05 to be strongly associated with eGFR, while polymorphisms with a P value < 0.05 were considered to be potentially associated with kidney function. The genetic risk score (GRS) was calculated as the sum of the total number of risk alleles. In addition, we also constructed a weighted model to reflect the difference in the effect of each risk variant. To estimate the effect size of each risk variant, we performed logistic regression analysis in which the dependent variable was the presence of CKD and the independent variables were eight SNPs. The weighted genetic risk score (wGRS) was appropriately calculated based on the estimated weights in the logistic regression analysis. Moreover, based on the logistic regression analysis, we appropriately assigned integer coefficients to each variant to construct the wGRS.

Subsequently, we evaluated the association between CKD and GRS. Multivariate logistic regression analysis adjusted for the factors that we obtained from health examination data and is associated adjusted for the factors obtained from the health examination data revealed an association with CKD. In the multivariable logistic regression analysis, we set three adjusting models as follows:

Model 1: adjusted for age, BMI, SBP, and FBG
Model 2: model 1 + exercise habit, drinking habit, smoking, and stress
Model 3: model 2 + LDL cholesterol, uric acid, and urinary protein through positive urine dipstick test

Model 1 contains major metabolic components and has a set of variables common in the multiple regression analysis of eGFR. Model 2 contains lifestyle information, which we selected based on literature review [23,24]. Model 3 contains other blood chemical tests, including urine dipstick test. Constructing multiple models enables the evaluation of whether lifestyle and other factors (e.g., proteinuria or serum uric acid) could affect GRS.

We also evaluated c-statistics, integrated discrimination improvement (IDI), and net reclassification improvement (NRI) to determine how the GRS improved outcome prediction [25,26]. IDI and NRI were assessed as category-free and thus could represent the average improvement in sensitivity across all possible cutoffs. P < 0.05 was considered statistically significant. The data were analyzed using Stata MP 14.2 (StataCorp LLC, Texas, USA).
Results
Clinical characteristics

Clinical characteristics (clinical parameters, lifestyle data, and meal purchase data) of the study participants are shown in Table 1. The number of the participants with CKD was 432 (9.85%). Participants with CKD were older and had higher BMI, SBP and DBP, BUN, UA, TG, LDL cholesterol, and FBG. The proportion of current smokers and daily drinkers was higher in the control group.

Linear regression analysis between SNPs and eGFR

S2 Table showed the univariate and multivariate regression analyses between eGFR and SNPs. In the multivariate linear regression adjusted for age, BMI, SBP, and FBG, we found eight candidate SNPs with P value < 0.05: CX3CR1 rs3732379, SHROOM3 rs17319721, MTP rs1800591, PIP5K1B rs4744712, APOA5 rs662799, BRAP rs3782886, SPATA5L1 rs2467853, and MCP1

Table 1. Clinical characteristics between the participants with or without chronic kidney disease.

| Characteristics                          | Number of data | Total CKD (N = 432) | Control (N = 4382) | P value |
|-----------------------------------------|----------------|---------------------|--------------------|---------|
| Age                                     | 4814           | 47.3±6.25           | 47.0±6.30          | <0.001* |
| Body mass index                         | 4814           | 23.7±3.44           | 23.6±3.42          | <0.001* |
| Systolic blood pressure (mmHg)          | 4814           | 121.2±13.8          | 121.0±13.7         | <0.001* |
| Diastolic blood pressure (mmHg)         | 4810           | 76.9±10.1           | 76.6±10.1          | <0.001* |
| Blood urea nitrogen (mg/dL)             | 4814           | 14.1±3.62           | 13.9±3.26          | <0.001* |
| Creatinine (mg/dL)                      | 4814           | 0.8 (0.8–0.9)       | 0.8 (0.8–0.9)      | <0.001* |
| eGFR (ml/min/1.73m²)                    | 4814           | 77.6±14.4           | 80.0±12.5          | <0.001* |
| Uric acid (mg/dL)                       | 4814           | 6.0±1.6             | 6.0±1.25           | 0.039*  |
| Total cholesterol (mg/dL)               | 4814           | 203±33.7            | 203±33.5           | 0.096   |
| Triglyceride (mg/dL)                    | 4813           | 102 (70–153)        | 101 (70–150)       | <0.001* |
| High density lipoprotein (mg/dL)        | 4814           | 58.2±15.1           | 57.0±16.1          | 0.10    |
| Low density lipoprotein (mg/dL)         | 4814           | 123.2±30.4          | 126.5±31.1         | 0.018*  |
| Fasting blood glucose                   | 4814           | 92 (87–99)          | 92 (87–99)         | 0.0032* |
| HbA1c                                   | 4814           | 5.32±0.64           | 5.32±0.64          | 0.55    |
| Urinary protein positivity on dipstick  | 4814           | 263.46%             | 204.46%            | <0.001* |
| Lifestyle                               |                |                     |                    |         |
| Exercise habits                         | 4805           |                     |                    | <0.001* |
| None                                    | 1562           | 32.51%              | 100, 23.26%        | 1462, 33.42% |
| <6 days per week                        | 2425           | 50.47%              | 248, 57.67%        | 2177, 49.76% |
| Every day                               | 818            | 17.02%              | 82, 19.07%         | 736, 16.82% |
| Drinking habits                         | 4806           |                     |                    | <0.001* |
| None                                    | 1130           | 23.51%              | 113, 26.28%        | 1017, 23.24% |
| <2 days per week                        | 1168           | 24.3%               | 123, 28.6%         | 1045, 23.88% |
| 3–6 days per week                       | 780            | 16.23%              | 77, 17.91%         | 703, 16.06% |
| Every day                               | 1728           | 35.96%              | 117, 27.21%        | 1611, 36.81% |
| Smoking                                 | 4810           | 1783, 37.07%        | 87, 20.19%         | 1696, 38.73% |
| Stress                                  | 4806           | 3921, 81.59%        | 339, 78.84%        | 3582, 81.86% |

CKD, chronic kidney disease. Continuous data are presented as mean ± SD or medians (1st quartile, 3rd quartile) and categorical data as n values (%). *P value < 0.05.

https://doi.org/10.1371/journal.pone.0185476.t001
rs1024611. Among these SNPs, BRAP rs3782886 and SPATA5L1 rs2467853 were significantly associated with eGFR (FDR < 0.05) (Table 2).

### Effects of genetic risk score on CKD

Linear regression analysis revealed eight candidate SNPs associated with kidney function. Subsequently, we calculated GRS by adding the total number of risk alleles. The mean value of GRS was 8.3 (±1.6), and the maximum and minimum values were 14 and 3, respectively.

Multiple models analyzing the association between GRS and CKD are shown in Table 3. After adjusting for relevant clinical factors, GRS was shown to be an independent factor associated with CKD. C-statistics showed marginally significant improvement by using GRS (P = 0.061), whereas IDI and NRI showed a significant improvement (P = 0.0028 and < 0.0001, respectively).

We constructed wGRS based on the logistic regression analysis shown in S3 Table. We multiplied the coefficient from the logistic regression analysis by 20 then added 25. The mean value of wGRS was 29.1 (±5.7), and the maximum and minimum values were 46 and 1, respectively.

Multiple models analyzing the association between wGRS and CKD are shown in S4 Table. We also showed that wGRS is an independent factor associated with CKD. C-statistics, IDI, INR, and NRI are calculated.

### Table 2. Multivariate linear regression analysis of the association between eGFR and SNPs.

| rs#    | Near gene | Major/minor allele | Risk allele | Coefficient | 95%CI         | P value | FDR |
|--------|-----------|--------------------|-------------|-------------|---------------|---------|-----|
| rs3732379 | CX3CR1    | C/T                | C           | 1.25        | (0.004, 2.50) | 0.049   | 0.36|
| rs17319721 | SHROOM3   | G/A                | A           | -1.16       | (-2.15, -0.16) | 0.023   | 0.24|
| rs1800591 | MTP       | G/T                | G           | 0.99        | (0.26, 1.72)  | 0.0077  | 0.13|
| rs4744712 | PIP5K1B   | C/A                | A           | -0.75       | (-1.31, -0.19) | 0.0088  | 0.13|
| rs662799  | APOA5     | A/G                | G           | -0.61       | (-1.18, -0.046) | 0.034   | 0.29|
| rs3782886 | BRAP      | A/G                | G           | -1.63       | (-2.25, -1.02) | <0.0001| <0.0001c |
| rs2467853 | SPATA5L1  | G/T                | G           | 2.07        | (0.89, 3.24)  | 0.0006  | 0.018c |
| rs1024611 | MCP1      | C/T                | T           | -0.65       | (-1.22, -0.084) | 0.025   | 0.24|

rs#, rs number; CI, confidence interval; FDR, false discovery rate

* The allele that decreased eGFR was defined as risk allele.

** Coefficient represents the value of eGFR increase as the number of minor allele increased by 1

^ FDR < 0.05.

https://doi.org/10.1371/journal.pone.0185476.t002

### Table 3. Univariate and multivariate logistic regression analysis of SNP Score and CKD.

|          | 95% CI | P value | C-statistics with GRS | C-statistics without GRS | P value | IDI | P value | NRI | P value |
|----------|--------|---------|-----------------------|--------------------------|---------|-----|---------|-----|---------|
| Univariate | 1.16  | [1.08–1.23] | <0.001 * | 0.562 | - | - | - | - | - |
| Model 1  | 1.17  | [1.10–1.25] | <0.001 * | 0.686 | 0.674 | 0.0090* | 0.0049 | <0.001* | 0.203 | <0.001* |
| Model 2  | 1.16  | [1.08–1.24] | <0.001 * | 0.713 | 0.706 | 0.062 | 0.0046 | <0.001* | 0.200 | <0.001* |
| Model 3  | 1.15  | [1.08–1.23] | <0.001 * | 0.716 | 0.709 | 0.061 | 0.0057 | <0.001* | 0.212 | <0.001* |

CI, confidence interval; GRS, genetic risk score; IDI, integrated discrimination improvement; NRI, net reclassification improvement. Model 1: adjusted for age, body mass index, systolic blood pressure, and fasting blood glucose. Model 2: model 1 + exercise habit, drinking habit, smoking, and stress. Model 3: model 2 + LDL cholesterol and fasting blood glucose, uric acid, and urinary protein through positive urine dipstick

* P < 0.05

https://doi.org/10.1371/journal.pone.0185476.t003
and NRI showed statistically significant improvement by using wGRS ($P = 0.040, < 0.001, < 0.001$, respectively).

**Discussion**

In this study, we showed a significant association between kidney function and genetic polymorphism, specifically **BRAP** rs3782886 and **SPATA5L1** rs2467853, after adjustment for clinical factors including lifestyle information. Moreover, we developed a GRS for chronic kidney disease, and used it in male workers who regularly undergo health checkups.

Several GWAS and candidate gene studies revealed the SNPs associated with kidney disease or kidney function [12–17]. Our study was unique as annual health examination data, particularly among middle-aged men, in a manufacturing company were used and a genetic risk score was developed. We developed a GRS combining the risk alleles in eight SNPs associated with kidney function, and examined its utility.

**BRAP** rs3782886 and **ALDH2** rs671 have strong linkage disequilibrium according to the HapMap database [27]. Meta-analysis of GWAS in East Asian populations showed associations between the SNP **ALDH2** rs671 and obesity and various cardiovascular risk factors and coronary artery disease (CAD) [28]. The minor allele of **ALDH2** rs671 was associated with CAD, high LDL, and low HDL, while the major allele was associated with high blood pressure, and high FBG. Another meta-analysis of GWAS in East Asian populations showed associations between the SNP **ALDH2** rs671 and kidney function [17] and revealed that the minor allele was associated with worse kidney function. In our study, the minor allele of **BRAP** rs3782886 was associated with lower kidney function, which is consistent with a previous study. A prospective study is necessary to investigate how **BRAP** rs3782886 affects the development of CVD and ESRD.

Moreover, similar to a previous study, our study also showed a significant association between **SPATA5L1** rs2467853 and kidney function [29]. **SPATA5L1** rs2467853 is an intronic SNP associated with glomerular filtration rate, which was estimated using serum creatinine, among European-descent participants from multiple cohorts; however, the biological significance remains unclear. Furthermore, a previous study showed that the **CX3CR1** rs3732379 SNP CC genotype is associated with increased risk of delayed graft function among patients who received renal transplantation [30]. In a study that first reported on the kidney function of a general population, **CX3CR1** rs3732379 SNP was associated with atherosclerosis of the coronary artery [31], **SHROOM3** rs17319721 and **PIP5K1B** rs4744712 were associated with kidney disease [29,32]. The minor allele of **MTP** rs1800591 was shown to be associated with hypertension in a Mexican population [33] and, in another study, with lower cholesterol level but ischemic heart disease [34]; in the present study, the major allele of **MTP** rs1800591 was associated with worse kidney function. No related study on kidney function exists; thus, further studies are needed. Moreover, **APOA5** rs662799 was associated with CKD in the Japanese general population [35]. **MCP1** rs1024611 was associated with carotid artery plaque, ischemic stroke (IS), and ischemic heart disease (IHD) [36,37]. The rs1024611C(G) allele is associated with increased serum MCP-1 levels and enhanced leukocyte recruitment to the tissues among Caucasians, which in turn could lead to atherosclerosis [38]. One meta-analysis showed that C (G) allele is a risk allele for IHD and IS [36], while some previous studies showed that T(A) is a risk allele for the development of diabetic nephropathy among the Asian population [39,40]. Whether **MCP1** rs1024611 causes arteriosclerosis via MCP-1 level change among Asians remains unclear; hence, further studies are needed.

Limitations of this study include the possibility of a sampling bias. Participation in the study was based on the willingness of individuals; consequently, the number of study
participants was limited. New findings have been accumulated since we started this research; thus, the selection of SNPs could also be a limitation. In addition, two further limitations regarding model construction in this study were noted: First, we used the same sample to get the weight for the weighted genetic score analysis. Thus, the results for weighted models could have been inflated. We could not have a different cohort to validate the effect of GRS. Hence, further studies should perform such an analysis with a different sample. Second, we also considered wGRS to reflect the difference in the effect of each variant. However, a comparison between the simple counting method (using GRS) and the scoring system (using wGRS) showed that AUCs were similar. Therefore, the simple counting of risk alleles could be feasible and useful. Lastly, the cross-sectional nature of this study limits our ability to estimate the longitudinal effects. Long-term observation of our study’s cohort will help in understanding and identifying individuals at a high risk of developing CKD and CVD.

In conclusion, a significant association between kidney function and genetic polymorphism, specifically \textit{BRAP} rs3782886 and \textit{SPATA5L1} rs2467853, exists. The GRS for chronic kidney disease that we developed was found to be useful in risk evaluation among middle-aged Japanese men. Nevertheless, validating the utility of GRS among other populations is necessary. In addition, a prospective observation of high-risk populations is warranted to confirm such association.

**Supporting information**

**S1 Table. Characteristics of genotyped SNPs.**

(DOCX)

**S2 Table. Crude and adjusted logistic regression analysis of association between eGFR and SNPs.**

(DOCX)

**S3 Table. Result of logistic regression analysis performed for weighting.**

(DOCX)

**S4 Table. Univariate and multivariate logistic regression analyses of weighted SNP score and CKD.**

(DOCX)

**S1 Dataset. Clinical data of 4814 study participants.**

(XLSX)

**Acknowledgments**

The authors would like to thank Toyota Motor Co., Ltd. for providing annual health examination data and for the support in developing medicine and promoting the health of their employees; Editage for providing editorial and publication support; and Ms. Hiraoka for SNP typing. Finally, we would also like to express our gratitude to Dr. Seiichi Matsuo, a former professor of the Department of Nephrology in Nagoya University Graduate School and currently the president of Nagoya University, for supporting the fundraising and constructing the research system.

**Author Contributions**

**Conceptualization:** Takahiro Imaizumi, Masahiko Ando.

**Data curation:** Yoko Kubo, Masahiko Ando.
Formal analysis: Yoko Kubo, Takahiro Imaizumi, Masahiko Ando.

Investigation: Yoshinari Yasuda, Hiroyuki Honda, Yachiyo Kuwatsuka, Sawako Kato, Kyoko Kikuchi.

Project administration: Yasuko Yoshida, Shoichi Maruyama.

Resources: Masamitsu Iwata, Toru Nakashima, Hiroshi Yasui, Hideki Takamatsu, Hiroshi Okajima.

Supervision: Yasuko Yoshida, Shoichi Maruyama.

Validation: Takaaki Kondo.

Visualization: Yoko Kubo.

Writing – original draft: Yoko Kubo, Takahiro Imaizumi, Masahiko Ando.

Writing – review & editing: Masahiro Nakatochi, Hiroyuki Honda, Takaaki Kondo.

References
1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004; 164: 659–663. https://doi.org/10.1001/archinte.164.6.659 PMID: 15037495
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296–1305. https://doi.org/10.1056/NEJMoa041031 PMID: 15385656
3. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002; 13: 745–753. PMID: 11856780
4. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003; 41: 47–55. PMID: 12570944
5. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009; 13: 621–630. https://doi.org/10.1007/s10157-009-0199-x PMID: 19513802
6. Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007; 71: 159–166. https://doi.org/10.1038/sj.ki.5002017 PMID: 17136030
7. Iseki K, Tozawa M, Ikemiya Y, Kinjo K, Iseki C, Takishita S. Relationship between dyslipidemia and the risk of developing end-stage renal disease in a screened cohort. Clin Exp Nephrol. 2005; 9: 46–52. https://doi.org/10.1007/s10157-004-0332-9 PMID: 15830273
8. Hashimoto Y, Tanaka M, Okada H, Senmaru T, Hamaguchi M, Asano M, et al. Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol. 2015; 10: 578–583. https://doi.org/10.2215/CJN.08890014 PMID: 25635035
9. Tozawa M, Iseki C, Tokashiki K, Chinen S, Kohagura K, Kinjo K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res. 2007; 30: 937–943. https://doi.org/10.1291/hypres.30.937 PMID: 18049025
10. Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006; 69: 399–374. https://doi.org/10.1038/sj.ki.5000950 PMID: 16408128
11. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004; 140: 167–174. PMID: 14757614
12. Yoshida T, Kato K, Fujimaki T, Yokoi K, Oguri M, Watanabe S, et al. Association of genetic variants with chronic kidney disease in Japanese individuals. Clin J Am Soc Nephrol. 2009; 4: 883–890. https://doi.org/10.102215/CJN.08980014 PMID: 89800808 PMCID: 19406964
13. Köttgen A, Pattaro C, Böger CA, Fuchsberger C, Olden M, Glazer NL, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet. 2010; 42: 376–84. https://doi.org/10.1038/ng.568 PMID: 20383146
14. Böger CA, Gorski M, Li M, Hoffmann MM, Huang C, Yang Q, et al. Association of eGFR-related loci identified by GWAS with incident CKD and ESRD. Kim SK, editor. PLoS Genet. 2011; 7: e1002292. https://doi.org/10.1371/journal.pgen.1002292 PMID: 21980298
Hishida A, Morita E, Naito M, Okada R, Wakai K, Matsu o K, et al. Associations of apolipoprotein A5

Gorski M, Tin A, Garnaas M, McMahon GM, Chu AY, Tayo BO, et al. Genome-wide association study

Okada Y, Sim X, Go MJ, Wu J-Y, Gu D, Takeuchi F, et al. Meta-analysis identifies multiple loci associ-

Nakatoch i M, Ushida Y, Yasuda Y, Yoshida Y, Kawai S, Kato R, et al. Identificati on of an interaction

Imaizumi T, Ando M, Nakato chi M, Yasuda Y, Honda H, Kuwats uka Y, et al. Effect of dietary energy

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR

Wakasugi M, Kazama JJ, Yamamoto S, Kawamura K, Narita I. A combinat ion of healthy lifestyle factors

Bo ¨ ger CA, Gorski M, Li M, Hoffmann MM, Huang C, Yang Q, et al. Association of eGFR-r elated loci

Rı ´ os-Gonza ´ lez BE, Ibarra-Corte ´ s B, Ramı ´ rez-Lo ´ pez G, Sa ´ nchez-Corona J, Maga

Ledmyr H, McMah on AD, Ehrenborg E, Nielsen LB, Neville M, Lithell H, et al. The microsomal triglycer-

15. Gorski M, Tin A, Garnaas M, McMahon GM, Chu AY, Tayo BO, et al. Genome-wide association study of kidney function decline in individuals of European descent. Kidney Int. 2015; 87: 1017–1029. https://doi.org/10.1038/ki.2014.361 PMID: 25493955

16. Hishida A, Morita E, Naito M, Okada R, Wakai K, Matsu o K, et al. Associations of apolipoprotein A5 (APOA5), glucokinase (GCK) and glucokinase regulatory protein (GCKR) polymorphisms and lifestyle factors with the risk of dyslipidemia and dysglycemia in Japanese—a cross-sectional data from the J-MICC Study. Endocr J. 2012; 59: 589–599. PMID: 22517333

17. Okada Y, Sim X, Go MJ, Wu J-Y, Gu D, Takeuchi F, et al. Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nat Genet. 2012; 44: 904–909. https://doi.org/10.1038/ng.2352 PMID: 22797727

18. Nakatoc hi M, Ushida Y, Yasuda Y, Yoshida Y, Kawai S, Kato R, et al. Identification of an interaction between VWF rs7965413 and platelet count as a novel risk marker for metabolic syndrome: an extensive search of candidate polymorphisms in a case-control study. PLoS One. 2015; 10: e0117591. https://doi.org/10.1371/journal.pone.0117591 PMID: 25646961

19. Imaizumi T, Ando M, Nakatoc hi M, Yasuda Y, Honda H, Kuwats uka Y, et al. Effect of dietary energy and polymorphisms in BRAP and GHRL on obesity and metabolic traits. Obes Res Clin Pract. 2016; May. pii: S1871-403X(16)30032-1. https://doi.org/10.1016/j.orcp.2016.05.004 PMID: 27245511

20. Imaizumi T, Ando M, Nakatoc hi M, Maruyama S, Yasuda Y, Honda H, et al. Association of interactions between dietary salt consumption and hypertension-susceptibility genetic polymorphisms with blood pressure among Japanese male workers. Clin Exp Nephrol. Epub 2016 Aug 1.

21. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982–992. https://doi.org/10.1053/j.ajkd.2008.12.034 PMID: 19339088

22. Nishida N, Tanabe T, Takasu M, Suyama A, Tokunaga K. Further development of multiplex single nucleotide polymorphism typing method, the DigiTag2 assay. Anal Biochem. 2007; 364: 78–85. https://doi.org/10.1016/j.ab.2007.02.005 PMID: 17359929

23. Wakasugi M, Kazama JJ, Yamamoto S, Kawamura K, Narita I. A combination of healthy lifestyle factors is associated with a decreased incidence of chronic kidney disease: a population-based cohort study. Hypertens Res. 2013; 36: 328–33. https://doi.org/10.1038/hr.2012.186 PMID: 23171933

24. Bruce MA, Griffith DM, Thorpe RJ. Stress and the kidney. Adv Chronic Kidney Dis. 2015; 22: 46–53. https://doi.org/10.1053/j.accd.2014.06.008 PMID: 25573512

25. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44: 837–845. PMID: 3203132

26. Pencina MJ, D’Agostino RB, D’Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27: 157–172. https://doi.org/10.1002/sim.2929 PMID: 17569110

27. The International HapMap Project. http://hapmap.ncbi.nlm.nih.gov/

28. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet. 2011; 43: 531–538. https://doi.org/10.1038/ng.834 PMID: 21572416

29. Köttgen A, Glazer NL, Dehghan A, Hwang S-J, Katz R, Li M, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet. 2009; 41: 712–717. https://doi.org/10.1038/ng.377 PMID: 19430482

30. Dabrowska-Zamojcin E, Dziedziejko V, Safranow K, Kurzawski M, Domanski L, Pawlik A. Association between the CX3CR1 gene V249I polymorphism and delayed kidney allograft function. Transpl Immunol. 2015; 32: 172–174. https://doi.org/10.1016/j.trim.2015.04.002 PMID: 25898802

31. McDermott DH, Halcox JP, Schenke WH, Waclawiw MA, Merrell MN, Epstein N, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res. 2001; 89: 401–407. PMID: 11532900

32. Böger CA, Gorski M, Li M, Hoffmann MM, Huang C, Yang Q, et al. Association of eGFR-related loci identified by GWAS with incident CKD and ESRD. PLoS Genet. 2011; 7: 3–10.

33. Ríos-González BE, Ibarra-Cortés B, Ramírez-López G, Sánchez-Corona J, Maña-Torres MT. Association of polymorphisms of genes involved in lipid metabolism with blood pressure and lipid values in Mexican hypertensive individuals. Dis Markers. 2014; 2013: 150358. https://doi.org/10.1155/2014/150358 PMID: 25587205

34. Ledmyr H, McMahon AD, Ehrenborg E, Nielsen LB, Neville M, Lithell H, et al. The microsomal triglycer-

PLOS ONE | https://doi.org/10.1371/journal.pone.0185476 October 10, 2017 10 / 11
disease. Circulation. 2004; 109: 2279–2284. https://doi.org/10.1161/01.CIR.0000130070.96758.7b PMID: 15136504

35. Hishida A, Wakai K, Naito M, Suma S, Sasakabe T, Hamajima N, et al. Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese—cross-sectional data from the J-MICC study. Lipids Health Dis. 2014; 13: 162. https://doi.org/10.1186/1476-511X-13-162 PMID: 25311932

36. Cai G, Zhang B, Weng W, Shi G, Huang Z. The associations between the MCP-1 −2518 A/G polymorphism and ischemic heart disease and ischemic stroke: a meta-analysis of 28 research studies involving 21,524 individuals. Mol Biol Rep. 2015; 42: 997–1012. https://doi.org/10.1007/s11033-014-3836-8 PMID: 25413568

37. Brenner D, Labreuche J, Touboul P-J, Schmidt-Petersen K, Poirier O, Perret C, et al. Cytokine polymorphisms associated with carotid intima-media thickness in stroke patients. Stroke. 2006; 37: 1691–1696. https://doi.org/10.1161/01.STR.0000226565.76113.6c PMID: 16741188

38. Pham MHT, Bonello GB, Castiblanco J, Le T, Sigala J, He W, et al. The rs1024611 regulatory region polymorphism is associated with CCL2 allelic expression imbalance. PLoS One. 2012; 7: e49498. https://doi.org/10.1371/journal.pone.0049498 PMID: 23166687

39. Mao S, Huang S. Monocyte chemoattractant protein-1 -2518G/A gene polymorphism and the risk of nephropathy in type 2 diabetes mellitus among Asians: a meta-analysis. Ren Fail. 2014; 36: 139–144. https://doi.org/10.3109/0886022X.2013.832690 PMID: 24059294

40. Su N, Li H-Y, Huang M-F, Jiang Z-P, Zhou T-B. Association of monocyte chemoattractant protein-1 2518G/A gene polymorphism with diabetic nephropathy risk. J Recept Signal Transduct Res. 2015; 35: 94–97. https://doi.org/10.3109/10799893.2014.936458 PMID: 25051493